Skip to main content

Table 6 Association between POAF and post-operative outcomes in 156 subjects

From: A double-blind randomised controlled trial on the effect of Tocovid, a tocotrienol-rich capsule on postoperative atrial fibrillation at the National Heart Institute, Kuala Lumpur: an interim blinded analysis

Post-operative outcomes Total*, n (%) Non-POAF group, n (%) POAF group, n (%) p value
Stroke
 Yes 4 (4.0) 2 (50) 2 (50) 0.58
 No 97 (96.0) 69 (71.1) 28 (28.9)  
Sternal infection
 Yes 3 (3.0) 3 (100) 0 (0) 0.55
 No 98 (97.0) 68 (69.4) 30 (30.6)  
Respiratory problems
 Yes 6 (5.9) 3 (50) 3 (50) 0.36
 No 95 (94.1) 68 (71.6) 27 (28.4)  
Renal failure requiring dialysis
 Yes 5 (5.0) 4 (80) 1 (20) 1.00
 No 96 (95.0) 67 (69.8) 29 (30.2)  
Endocrine problems
 Yes 1 (1.0) 1 (100.0) 0 (0) 1.00
 No 100 (99.0) 70 (70.0) 30 (30.0)  
Pleural effusion
 Yes 5 (5.0) 3 (60) 2 (40) 0.63
 No 96 (95.0) 68 (70.8) 28 (29.2)  
Cardiac tamponade
 Yes 14 (13.9) 13 (92.9) 1 (7.1) 0.06
 No 87 (86.1) 58 (66.7) 29 (33.3)  
Fever
 Yes 6 (5.9) 4 (66.7) 2 (33.3) 1.00
 No 95 (94.1) 67 (70.5) 28 (29.5)  
Hyperkalaemia
 Yes 4 (4.0) 3 (75) 1 (25) 1.00
 No 97 (96.0) 68 (70.1) 29 (29.9)  
Others
 Yes 3 (3.0) 1 (33.33) 2 (66.7) 0.21
 No 98 (97.0) 70 (71.4) 28 (28.6)  
Death
 Yes 8 (7.9) 2 (25) 6 (75) 0.008*
 No 93 (92.1) 69 (74.2) 24 (25.8)  
  1. Others: Low blood pressure, multiple premature ventricular complexes
  2. Total n varies slightly for each item due to a small amount of missing data in each
  3. *p value significant at < 0.05 using the Fisher Exact test